23 May 2013
Keywords: avonex, gets, eu, ok, high-risk, ms, patients
Article | 27 May 2002
Biogen has been under pressure to protect its multiple sclerosisfranchise of late in the face of growing competition, and news ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
27 May 2002
3 June 2002
© 2013 thepharmaletter.com